Figure 2 | Scientific Reports

Figure 2

From: Thyroglobulin fluctuations in patients with iodine-refractory differentiated thyroid carcinoma on lenvatinib treatment – initial experience

Figure 2

Example of the influence of dose reductions of lenvatinib on serum thyroglobulin levels.

Whereas patient #5 (left) exhibited rising Tg levels after reducing the dose from 24 mg to 20 mg, tumor marker levels decreased or remained stable after several reductions from 24 mg to 10 mg in patient #6 (right). On computed tomography, both patients presented with a partial response (partient #5) and stable disease (patient #6) throughout follow-up.

Back to article page